In patients with stage IV melanoma with distant metastases, what is the response rate to an oral inhibitor of the protein kinase BRAF? Background: There are few effective therapies for patients with stage IV metastatic melanoma. Response rates to standard therapy (interleukin-2 or dacarbazine) are 10 to 20 percent, and complete responses are exceedingly rare. The […]
